{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T04:11:04Z","timestamp":1748751064507,"version":"3.41.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T00:00:00Z","timestamp":1447977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1038\/eye.2015.240","type":"journal-article","created":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T10:31:45Z","timestamp":1448015505000},"page":"392-399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Serial evaluation of retinal vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in zone I"],"prefix":"10.1038","volume":"30","author":[{"given":"T R","family":"Padhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Rath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Sutar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K G","family":"Panda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Modi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,20]]},"reference":[{"issue":"12","key":"BFeye2015240_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.earlhumdev.2012.09.019","volume":"88","author":"HA Mintz-Hittner","year":"2012","unstructured":"Mintz-Hittner HA . Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors. Early Hum Dev 2012; 88 (12): 937\u2013941.","journal-title":"Early Hum Dev"},{"issue":"1","key":"BFeye2015240_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ophtha.2014.07.050","volume":"122","author":"ME Hartnett","year":"2015","unstructured":"Hartnett ME . Pathophysiology and mechanism of severe retinopathy of prematurity. Ophthalmology 2015; 122 (1): 200\u2013210.","journal-title":"Ophthalmology"},{"issue":"4","key":"BFeye2015240_CR3","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.clp.2014.08.011","volume":"41","author":"ME Hartnett","year":"2014","unstructured":"Hartnett ME . Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity. Clin Perinatol 2014; 41 (4): 925\u2013943.","journal-title":"Clin Perinatol"},{"key":"BFeye2015240_CR4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"An International Committee for the Classification of Retinopathy of Prematurity","year":"2005","unstructured":"An International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity Revisited. Arch Ophthalmol 2005; 123: 991\u2013999.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2015240_CR5","first-page":"228","volume":"6","author":"FM Mutlu","year":"2013","unstructured":"Mutlu FM, Sarici FU . Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options. Int J Ophthalmol 2013; 6: 228\u2013236.","journal-title":"Int J Ophthalmol"},{"issue":"12","key":"BFeye2015240_CR6","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity randomized trial. Arch Ophthalmol 2003; 121 (12): 1684\u20131694.","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"BFeye2015240_CR7","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ajo.2006.05.048","volume":"142","author":"N Azuma","year":"2006","unstructured":"Azuma N, Ishikawa K, Hama Y, Hiraoka M, Suzuki Y, Nishina S . Early vitreous surgery for aggressive posterior retinopathy of prematurity. Am J Ophthalmol 2006; 142 (4): 636\u2013643.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"BFeye2015240_CR8","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ajo.2007.10.027","volume":"145","author":"A Vinekar","year":"2008","unstructured":"Vinekar A, Trese MT, Capone A Jr . Evolution of retinal detachment in posterior retinopathy of prematurity: impact on treatment approach. Am J Ophthalmol 2008; 145 (3): 548\u2013555.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"BFeye2015240_CR9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1001\/archophthalmol.2010.72","volume":"128","author":"WV Good","year":"2010","unstructured":"Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Tung B et al. Final visual acuity results in the early treatment for retinopathy of prematurity study. Arch Ophthalmol 2010; 128 (6): 663\u2013671.","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"BFeye2015240_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ,, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011; 364 (7): 603\u2013615.","journal-title":"N Engl J Med"},{"issue":"3","key":"BFeye2015240_CR11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4103\/0974-620X.142592","volume":"7","author":"PK Shah","year":"2014","unstructured":"Shah PK, Ramakrishnan M, Sadat B, Bachu S, Narendran V, Kalpana N . Long term refractive and structural outcome following laser treatment for zone 1 aggressive posterior retinopathy of prematurity. Oman J Ophthalmol 2014; 7 (3): 116\u2013119.","journal-title":"Oman J Ophthalmol"},{"issue":"1","key":"BFeye2015240_CR12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0022-3565(24)37962-5","volume":"288","author":"YS Lin","year":"1999","unstructured":"Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999; 288 (1): 371\u2013378.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"BFeye2015240_CR13","doi-asserted-by":"publisher","first-page":"F170","DOI":"10.1136\/archdischild-2011-301148","volume":"98","author":"BA Darlow","year":"2013","unstructured":"Darlow BA, Ells AL, Gilbert C.E, Gole GA, Quinn GE . Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed 2013; 98 (2): F170\u2013F174.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"2","key":"BFeye2015240_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","volume":"153","author":"T Sato","year":"2012","unstructured":"Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012; 153 (2): 327\u2013333.e1.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"BFeye2015240_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","volume":"118","author":"WC Wu","year":"2011","unstructured":"Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK . Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan. Ophthalmology 2011; 118 (1): 176\u2013183.","journal-title":"Ophthalmology"},{"key":"BFeye2015240_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3129\/i10-027","volume":"45","author":"JA Micieli","year":"2010","unstructured":"Micieli JA, Micieli A, Smith AF . Identifying systemic safety signals following intravitreal bevacizumab: systematic review of the literature and the Canadian Adverse Drug Reaction Database. Can J Ophthalmol 2010; 45: 231\u2013238.","journal-title":"Can J Ophthalmol"},{"key":"BFeye2015240_CR17","unstructured":"Pejaver RK, Vinekar A, Bilagi A. National Neonatology Forum, Evidence Based Clinical Practice Guidelines, Chapter on Retinopathy of Prematurity, NNF India, Guidelines 2010, pp 253-262. Available at: http:\/\/aimaonline.org\/iap-neochap-2013\/uploads\/acd-corner\/nnf_guidelines-2011.pdf (accessed 11 November 2015)."},{"issue":"5 Suppl","key":"BFeye2015240_CR18","doi-asserted-by":"publisher","first-page":"s3","DOI":"10.1097\/00006982-200410001-00002","volume":"24","author":"LP Aiello","year":"2004","unstructured":"Aiello LP, Brucker AJ, Chang S, Cunningham ET Jr, D\u2019Amico DJ, Flynn HW Jr et al. Evolving guidelines for intravitreous injections. Retina 2004; 24 (5 Suppl): s3\u2013s19.","journal-title":"Retina"},{"issue":"3 Suppl","key":"BFeye2015240_CR19","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","volume":"28","author":"H Quiroz-Mercado","year":"2008","unstructured":"Quiroz-Mercado H, Martinez-Castellanos MA, Hermamdez-Rojas ML, Salazar-TeranN, Chan RV . Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008; 28 (3 Suppl): S19\u2013S25.","journal-title":"Retina"},{"key":"BFeye2015240_CR20","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","volume":"28","author":"HA Mintz-Hittner","year":"2008","unstructured":"Mintz-Hittner HA, Kuffel RR Jr . Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008; 28: 831\u2013838.","journal-title":"Retina"},{"issue":"5","key":"BFeye2015240_CR21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/ped.12124","volume":"55","author":"A \u015eahin","year":"2013","unstructured":"\u015eahin A, \u015eahin M, Cing\u00fc AK, \u00c7\u0131nar Y, T\u00fcrkc\u00fc FM, Y\u00fcksel H et al. Intravitreal bevacizumab monotherapy for retinopathy of prematurity. Pediatr Int 2013; 55 (5): 599\u2013603.","journal-title":"Pediatr Int"},{"issue":"11","key":"BFeye2015240_CR22","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.3109\/14767058.2012.684109","volume":"25","author":"C Dani","year":"2012","unstructured":"Dani C, Frosini S, Fortunato P, Bertini G, Pratesi S, Pollazzi L et al. Intravitreal bevacizumab for retinopathy of prematurity as first line or rescue therapy with focal laser treatment. A case series. J Matern Fetal Neonatal Med 2012; 25 (11): 2194\u20132197.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"7","key":"BFeye2015240_CR23","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1056\/NEJMe1100248","volume":"364","author":"JD Reynolds","year":"2011","unstructured":"Reynolds JD . Bevacizumab for retinopathy of prematurity. N Engl J Med 2011; 364 (7): 677\u2013678.","journal-title":"N Engl J Med"},{"issue":"8","key":"BFeye2015240_CR24","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/archophthalmol.2008.1","volume":"126","author":"L Kong","year":"2008","unstructured":"Kong L, Mintz-Hittner HA, Penland RL, Kretzer FL, Chevez-Barrios P . Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol 2008; 126 (8): 1161\u20131163.","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"BFeye2015240_CR25","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R . Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 2012; 130 (8): 1000\u20131006.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"BFeye2015240_CR26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jaapos.2013.12.009","volume":"18","author":"A Henaine-Berra","year":"2014","unstructured":"Henaine-Berra A, Garcia-Aguirre G, Quiroz-Mercado H, Martinez-Castellanos MA . Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy. J AAPOS 2014; 18 (2): 120\u2013123.","journal-title":"J AAPOS"},{"issue":"4","key":"BFeye2015240_CR27","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","volume":"98","author":"SG Tahija","year":"2014","unstructured":"Tahija SG, Hersetyati R, Lam GC, Kusaka S, McMenamin PG . Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol 2014; 98 (4): 507\u2013512.","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"BFeye2015240_CR28","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","volume":"121","author":"D Lepore","year":"2014","unstructured":"Lepore D, Quinn GE, Molle F, Baldascino A, Orazi L, Sammartino M et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology 2014; 121 (11): 2212\u20132219.","journal-title":"Ophthalmology"},{"issue":"10","key":"BFeye2015240_CR29","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00417-014-2867-0","volume":"253","author":"H Yetik","year":"2014","unstructured":"Yetik H, Gunay M, Sirop S, Salihoglu Z . Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity\u201427 month follow-up results from Turkey. Graefes Arch Clin Exp Ophthalmol 2014; 253 (10): 1677\u20131683.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"BFeye2015240_CR30","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1016\/j.ophtha.2014.05.029","volume":"121","author":"AH Kashani","year":"2014","unstructured":"Kashani AH, Brown KT, Chang E, Drenser KA, Capone A, Trese MT . Diversity of retinal vascular anomalies in patients with familial exudative vitreoretinopathy. Ophthalmology 2014; 121 (11): 2220\u20132227.","journal-title":"Ophthalmology"},{"key":"BFeye2015240_CR31","doi-asserted-by":"publisher","first-page":"F327","DOI":"10.1136\/archdischild-2012-302365","volume":"98","author":"S Jalali","year":"2013","unstructured":"Jalali S, Balakrishnan D, Zeynalova Z, Padhi TR, Rani PK . Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Screening database Report number 5. Arch Dis Child Fetal Neonatal Ed 2013; 98: F327\u2013F333.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"4","key":"BFeye2015240_CR32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3109\/08820538.2013.835842","volume":"29","author":"J Chhablani","year":"2014","unstructured":"Chhablani J, Rani PK, Balakrishnan D, Jalali S . Unusual adverse choroidal reaction to intravitreal bevacizumab in aggressive posterior retinopathy of prematurity: the Indian Twin Cities ROP screening (ITCROPS) data base report number 7. Semin Ophthalmol 2014; 29 (4): 222\u2013225.","journal-title":"Semin Ophthalmol"},{"issue":"2","key":"BFeye2015240_CR33","first-page":"228","volume":"6","author":"FM Mutlu","year":"2013","unstructured":"Mutlu FM, Sarici SU . Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options. Int J Ophthalmol 2013; 6 (2): 228\u2013236.","journal-title":"Int J Ophthalmol"},{"issue":"7","key":"BFeye2015240_CR34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/jp.2009.166","volume":"30","author":"LO Atchaneeyasakul","year":"2010","unstructured":"Atchaneeyasakul LO, Trinavarat A . Choroidal ruptures after adjuvant intravitreal injection of bevacizumab for aggressive posterior retinopathy of prematurity. J Perinatol 2010; 30 (7): 497\u2013499.","journal-title":"J Perinatol"},{"issue":"4","key":"BFeye2015240_CR35","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","volume":"133","author":"WC Wu","year":"2015","unstructured":"Wu WC, Lien R, Liao PJ, Wang NK, Chen YP, Chao AN et al. Serum levels of vascular endothelial growth factors and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol 2015; 133 (4): 391\u2013397.","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"BFeye2015240_CR36","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1111\/j.1651-2227.2011.02445.x","volume":"100","author":"AL Hard","year":"2011","unstructured":"Hard AL, Hellstrom A . On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment: a review. Acta Paediatr 2011; 100 (12): 1523\u20131527.","journal-title":"Acta Paediatr"},{"issue":"3","key":"BFeye2015240_CR37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10384-014-0310-z","volume":"58","author":"K Kuniyoshi","year":"2014","unstructured":"Kuniyoshi K, Sugioka K, Sakuramoto H, Kusaka S, Wada N, Shimomura Y . Intravitreal injection of bevacizumab for retinopathy of prematurity. Jpn J Ophthalmol 2014; 58 (3): 237\u2013243.","journal-title":"Jpn J Ophthalmol"},{"issue":"6","key":"BFeye2015240_CR38","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/aos.12266","volume":"92","author":"BC Harder","year":"2014","unstructured":"Harder BC, von Balz S, Jonas JB, Schlichtenbrede FC . Intravitreal low-dosage bevacizumab for retinopathy of prematurity. Acta Ophthalmol 2014; 92 (6): 577\u2013581.","journal-title":"Acta Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/eye2015240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2015240","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2015240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T13:11:01Z","timestamp":1748697061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/eye2015240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,20]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["BFeye2015240"],"URL":"https:\/\/doi.org\/10.1038\/eye.2015.240","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"type":"print","value":"0950-222X"},{"type":"electronic","value":"1476-5454"}],"subject":[],"published":{"date-parts":[[2015,11,20]]},"assertion":[{"value":"5 June 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}